title: Serum levels of CA 125 and TPS during treatment of ovarian cancer.
abstract: Two hundred and sixty ovarian cancer patients (including all FIGO stages) were enrolled in a prospective multicentre study. In this interim study we analyzed 206 patients receiving combined chemotherapy for at least 3 courses for two-year overall survival (OS). CA 125 and TPS were applied for monitoring treatment and the relationship between marker levels, marker changes and clinical assessments was established. Preoperative CA 125 or TPS levels were not correlated with OS in FIGO stage I and II patients. After 3 chemotherapy courses the marker levels were not correlated with OS in stage I and II. Partial debulking in stage II patients was a bad prognostic factor. CA 125 or TPS levels (using a CA 125 discrimination level of 25 kU/l and a TPS discrimination level of 100 U/l) after 3 courses of chemotherapy were highly significantly correlated with OS in FIGO stages III and IV patients: CA 125 two-year OS 67% versus 26% (p < 0.0001) and TPS two-year OS 55% versus 22% (p < 0.0001). The prognostic value of CA 125 levels after 3 chemotherapy courses could be further increased by combining CA 125 and TPS levels. When both CA 125 and TPS levels were below their respective discrimination levels, the two-year overall survival was 75%. When both levels were above the discrimination level, the two-year overall survival was only 17%.
authors.affiliation: Groene Hart Ziekenhuis, Gouda, The Netherlands. Tmoncology@cs.com
authors.forename: A
authors.initials: A
authors.lastname: Van Dalen
authors.forename: J
authors.initials: J
authors.lastname: Favier
authors.forename: L
authors.initials: L
authors.lastname: Baumgartner
authors.forename: U
authors.initials: U
authors.lastname: Hasholzner
authors.forename: H
authors.initials: H
authors.lastname: De Bruijn
authors.forename: D
authors.initials: D
authors.lastname: Dobbler
authors.forename: V H
authors.initials: VH
authors.lastname: Dombi
authors.forename: D
authors.initials: D
authors.lastname: Fink
authors.forename: M
authors.initials: M
authors.lastname: Giai
authors.forename: P
authors.initials: P
authors.lastname: McGing
authors.forename: A
authors.initials: A
authors.lastname: Harlozinska
authors.forename: C
authors.initials: C
authors.lastname: Kainz
authors.forename: J
authors.initials: J
authors.lastname: Markowska
authors.forename: R
authors.initials: R
authors.lastname: Molina
authors.forename: C
authors.initials: C
authors.lastname: Sturgeon
authors.forename: A
authors.initials: A
authors.lastname: Bowman
authors.forename: R
authors.initials: R
authors.lastname: Einarsson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D010455:Peptides / Q000097:blood*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D010455:Peptides; C089984:tissue polypeptide specific antigen